A general assessment of the safety of HMG CoA reductase inhibitors (statins).

被引：50

作者：

Black D.M. ^{[1
]}

机构：

[1] Medical Research Laboratories International, Highland Heights, 2 Tesseneer Avenue, 41076, KY

来源：

Current Atherosclerosis Reports | 2002年 / 4卷 / 1期

关键词：

Statin; Simvastatin; Atorvastatin; Myopathy; Pravastatin;

D O I：

10.1007/s11883-002-0060-0

中图分类号：

学科分类号：

摘要：

Few principles in medicine today are as well accepted as the benefits of using statins to reduce cardiovascular risk factors and to prevent cardiovascular disease. The recent withdrawal of a statin (cerivastatin) has lead to a re-examination of all statins, and an attempt to better assess the risk-benefit ratio of this class of drugs. Although the benefits of statin treatment are well known from a myriad of clinical trials, the safety of these compounds has not been an issue since lovastatin was first introduced in 1987. This report provides a brief review of statin safety, and reiterates the excellent profile of this class of drugs.

引用

页码：34 / 41

页数：7

共 69 条

[11] Pfeffer MA(1994)Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryll-coenzyme A reductase Am J Cardiol 73 3D-11D
[12] Moye LA(1991)Long-term safety and efficacy profile of simvastatin Am J Cardiol 68 1127-1131
[13] Pederson TR(2000)A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britian Drug Safety 23 165-172
[14] Berg K(1999)Aggressive lipid-lowering therapy compared with angioplastyin stable coronary artery disease N Engl J Med 341 70-76
[15] Cook TJ(2001)Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study JAMA 285 1711-1718
[16] Downs JR(1995)Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens Am J Cardiol 75 1130-1134
[17] Clearfield M(2000)Comparativve tolerability of the HMG CoA reductase inhibitors Drug Safety 23 197-213
[18] Weis S(2000)Long-term safety of hepatic hydroxymethyl glutaryl Coenzyme A reductase inhibitors Arch Intern Med 160 2273-2280
[19] Tobert JA(2001)Safety of statins: different mechanisms of metabolism and drug transport may have clinical relevance Arch Intern Med 161 1012-1012
[20] Shear CL(2000)Safey profile of atorvastatin treated patietns with low LDL-cholesterol levels Atherosclerosis 149 123-129

← 1 2 3 4 5 6 7 →